Johnson A J, Beets J L
Br J Clin Pharmacol. 1979 May;7(5):511-3. doi: 10.1111/j.1365-2125.1979.tb00995.x.
1 The absorption of PRD-92 Ea, a new anti-allergy drug, was studied in volunteer subjects. 2 The 14C-labelled drug was administered orally and the radioactivity measured in plasma, urine and faeces. 3 Mean peak plasma concentration was 3.3 micrograms/ml, with a concentration of over 1 micrograms/ml maintained 4 h after administration. 4 The mean plasma half-life (T 1/2) was 114 min. 5 The mean percentage recovery in the urine was 9.5%. 6 Oral administration leads to significant and sustained plasma concentrations, and the oral route should be suitable for drug evaluation in clinical practice.
对一种新型抗过敏药物PRD - 92 Ea在志愿者体内的吸收情况进行了研究。
口服给予14C标记的药物,并测定血浆、尿液和粪便中的放射性。
血浆平均峰值浓度为3.3微克/毫升,给药后4小时内浓度维持在1微克/毫升以上。
血浆平均半衰期(T 1/2)为114分钟。
尿液中的平均回收率为9.5%。
口服给药可导致血浆浓度显著且持续升高,口服途径应适用于临床实践中的药物评估。